- Home
- MACI vs ELDN Comparison
MACI vs ELDN Comparison
Compare MACI & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MACI
- ELDN
- Stock Information
- Founded
- MACI 2024
- ELDN 2004
- Country
- MACI United States
- ELDN United States
- Employees
- MACI N/A
- ELDN N/A
- Industry
- MACI
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- MACI
- ELDN Health Care
- Exchange
- MACI NYSE
- ELDN Nasdaq
- Market Cap
- MACI 221.6M
- ELDN 178.4M
- IPO Year
- MACI 2024
- ELDN N/A
- Fundamental
- Price
- MACI $10.37
- ELDN $3.00
- Analyst Decision
- MACI
- ELDN Strong Buy
- Analyst Count
- MACI 0
- ELDN 1
- Target Price
- MACI N/A
- ELDN $16.00
- AVG Volume (30 Days)
- MACI 9.4K
- ELDN 209.1K
- Earning Date
- MACI 01-01-0001
- ELDN 05-14-2025
- Dividend Yield
- MACI N/A
- ELDN N/A
- EPS Growth
- MACI N/A
- ELDN N/A
- EPS
- MACI 0.33
- ELDN N/A
- Revenue
- MACI N/A
- ELDN N/A
- Revenue This Year
- MACI N/A
- ELDN N/A
- Revenue Next Year
- MACI N/A
- ELDN N/A
- P/E Ratio
- MACI $31.51
- ELDN N/A
- Revenue Growth
- MACI N/A
- ELDN N/A
- 52 Week Low
- MACI $9.95
- ELDN $2.30
- 52 Week High
- MACI $10.40
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- MACI N/A
- ELDN 46.32
- Support Level
- MACI N/A
- ELDN $3.00
- Resistance Level
- MACI N/A
- ELDN $3.27
- Average True Range (ATR)
- MACI 0.00
- ELDN 0.18
- MACD
- MACI 0.00
- ELDN 0.02
- Stochastic Oscillator
- MACI 0.00
- ELDN 40.00
About MACI MELAR ACQUISITION CORP. I
Melar Acquisition Corp I is a blank check company.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.